Clinical ink Gets New Equity From Ardan and GI Partners

Clinical ink is carrying technology built for scheduled studies into the much less scheduled business of daily life. Its expansion into clinical care gives the Winston-Salem, North Carolina company a new setting for its work with electronic assessments, connected devices and patient behavior.

On October 19, 2026, Clinical ink announced new equity investments from Ardan Equity and GI Partners in a co-control partnership. Ardan Equity Fund I and GI Partners Fund VI invested, while earlier investors, including GI Partners Fund V, exited their prior holdings. The announcement disclosed no investment amount.

For pharmaceutical companies and contract research organizations, the commercial question reaches beyond collecting another measurement. Clinical ink is building around the relationship between the data a study needs and the person expected to keep providing it, with tools such as GlucoseReady and the newer Kaitality application extending that work across research and care. Moving between those settings brings patient participation into the investment story alongside the software itself.

A new ownership period for a familiar company

GI Partners has backed Clinical ink since completing its acquisition in August 2020. The latest transaction gives the firm's earlier fund an exit while a later fund invests alongside Ardan, preserving an institutional relationship through a change in the capital behind it. The distinction matters for understanding what the announcement actually finances.

Both firms invested new equity, according to the release. The public account does not divide the transaction between money available to the company and proceeds paid to existing shareholders, so there is no reliable basis for treating the whole deal as a product-development budget. Valuation and ownership percentages were also absent from the announcement.

Ardan Equity specializes in healthcare and life sciences technology, with clinical-trials enablement among its stated investment themes. Managing Partner Noah Lewis described Clinical ink as the first investment from Ardan Equity Fund I. GI Partners Managing Director and Head of Healthcare Dave Kreter pointed to the company's development since 2020, while CEO Jonathan Goldman will work with both firms on the next phase. The stated plan is to expand the platform globally and pursue opportunities in clinical research and clinical care; specific spending allocations were not published.

The original problem was a copied observation

Clinical ink's history helps explain why its product portfolio keeps returning to the moment data enters a system. Co-founders Doug Pierce and Tommy Littlejohn built the company around electronic source-data capture, an effort that Doug Pierce discussed in a 2014 interview. Reentering information from paper created opportunities for error and additional monitoring work. Recording the observation electronically at the encounter moved that work closer to its origin.

That operating concern remains recognizable even as the devices change. Clinical ink's portfolio now includes electronic clinical outcome assessments, or eCOA, direct data capture, consent tools and connected devices. Pharmaceutical sponsors and CROs need information that can survive the trip from a patient interaction to analysis, with enough context to explain what was measured and how.

The surrounding workflow is attracting other kinds of software investment, too. DevCuration's coverage of Intake AI's source-document tools follows the work required to prepare a study visit, while Peppermint's trial-finance software addresses the records needed to get sites paid. These businesses approach different tasks, but their proximity exposes how many people and systems sit around a single clinical encounter. Clinical ink operates inside the collection and interpretation of patient data, where every additional handoff can become somebody's reconciliation job.

A device reading needs a usable study around it

Clinical ink's GlucoseReady announcement offers a concrete example of connecting those tasks. The company describes a platform combining blood and continuous glucose monitoring with electronic assessments, plus integrations for weight scales and activity devices. Glucose measurements can trigger a hypoglycemia assessment, connecting a sensor event with information about the patient's experience. Those are company-described capabilities rather than an independent comparison with competing systems.

The useful product question is what happens around the measurement. A trial team needs the technology to fit its study, participants need to be able to use it, and the resulting data has to support the investigation. Adding devices widens the record available to researchers while adding decisions about training, usability and incomplete observations.

The FDA's final guidance on remote data acquisition provides a framework for that work. In its accompanying discussion, the agency emphasizes fit-for-purpose verification, validation and usability, as well as the potential for technology-use problems to create missing data. For buyers, that makes implementation part of the product evaluation. Clinical ink's mix of assessment software, devices and endpoint expertise is aimed at the combined task, where a well-designed collection method still depends on a participant being willing and able to use it.

Taking the relationship beyond the trial

Kaitality gives Clinical ink's care expansion a defined starting point. The company describes an app combining personalized medication-adherence support with weight, body-composition and activity measurements, initially aimed at U.S. patients with obesity taking incretin- or amylin-based medicines. Its announced route begins with observational studies before wider use in patient-support programs and by the payer market. That sequence keeps the commercial ambition distinct from evidence of broad deployment.

The move also changes the working relationship. A research participant follows a study's schedule, while continuing care has to accommodate routines that change after the appointment ends. Clinical ink is trying to carry its experience with assessments and engagement into that less controlled environment. The investment supplies partners for the expansion, but the public material does not establish how many patients will adopt Kaitality or what outcomes it will achieve.

Kaitality's proposed progression from observational studies to patient-support programs would put the same measurements in front of different decision-makers. Clinical ink's new owners are joining as the company works out how that information can remain useful to the next organization responsible for the patient's care.